Clinical Trial Highlights

• ODYSSEY COMBO II: Alirocumab Significantly Improves Cholesterol Levels in Patients with High CV Risk
• PARADIGM-HF: Novel Drug Reduced Outcomes, Improved Symptoms Better Than ACE Inhibition
• NECTAR-HF: Cardiac Remodeling Not Reduced with VNS
• SIGNIFY: Treatment with Ivabradine Does Not Improve Outcomes and May Increase Risk in Patients with Angina
• CONFIRM-HF: Novel Approach Treating ID Improved Function, Symptoms, and QOL
• POPE-2: No Benefit with Colchicine to Reduce Persistent Postoperative Pericardial Effusion
• COPPS-2: Colchicine Reduced PPS in Cardiac Surgery Patients
• Darapladib Ineffective at Reducing Major Coronary Events after ACS
• Prehospital Ticagrelor Reduces Stent Thrombosis in STEMI
• ODYSSEY FH I and FH II: Alirocumab Significantly Improves Cholesterol Levels in Patients with HeFH
• IBIS-4: High-Dose Rosuvastatin Reduces Plaque Burden in Patients with STEMI
• NO Fails to Reduce Myocardial IS: NOMI Results
• TRO40303 Lacks Protective Effect in PCI: Results from MITOCARE
• ENGAGE AF-TIMI 48: Tailoring Edoxaban Dose Preserves Drug Efficacy and Safety
• X-VeRT Results: Rivaroxaban is Safe and Effective for Cardioversion in AF
• FAMOUS NSTEMI: FFR-Guided Management of NSTEMI Reduces PCI and CABG
• STABILITY: Darapladib and Lp-PLA₂ Levels in Treatment of Atherosclerosis
• FAME 2: FFR—Guided PCI Reduces Urgent Revascularization